BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...

For the fourth quarter of 2025, Ginkgo Bioworks reported a strategic pivot towards robotics and AI, with CEO Jason Kelly emphasizing the company’s collaboration with the Department of Energy and ...

Earnings Call Insights: Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Jason Kelly, Founder, CEO & Director, emphasized Ginkgo’s mission to "make biology easier to engineer" and outlined three major ...

Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO. Thanks, as always, for joining us. We're ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings Inc (NYSE:DNA) is one of the best small cap agriculture stocks to buy now. Ginkgo Bioworks is developing an autonomous lab that it calls Nebula. Biotech companies can use this ...

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It ...

Ginkgo Bioworks DNA shares are down following the company’s fourth-quarter and full-year 2025 financial report. The stock’s decline comes as the company is focusing on investing in autonomous labs.

Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership at Ginkgo. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO. Thanks, as always, for joining ...